Hi-Great Group Holding Company
Key statistics
from XBRL data in SEC filingsAI briefing
from the latest 10-K, 10-Q and 8-K eventsHi-Great Group Holding Co is a development-stage Nevada shell company pivoting from CBD oils to KRAS gene-related cancer treatments and longevity supplements.
What they do
The company identifies as a development stage enterprise with no substantive revenue-producing operations described in the filings. It has withdrawn CBD oils from its business plan and now holds an exclusive worldwide license for a new business plan related to the KRAS gene, a mutation common in cancers. It also continues to market, sell, and distribute SellaCare, Inc.'s organic longevity health supplement under an exclusive worldwide license. The website is listed as under construction.
Revenue drivers
- KRAS gene license — Exclusive worldwide license for a new business plan centered on KRAS gene mutations; no revenue or product details provided.
- SellaCare longevity supplement — Exclusive worldwide distribution of SellaCare's organic longevity health supplement; no revenue figures reported for this segment.
Recent performance
Annual revenue declined from $264,194 in 2021 to $36,958 in 2025, with net losses widening to $87,208 in 2025. Operating cash flow was negative $89,609 in 2025. Quarterly revenue in the three months ended March 31, 2026 was $13,255, down from $15,500 in the prior quarter but up from $2,440 in the quarter ended December 31, 2025. As of March 31, 2026, total assets were $22,105, total liabilities $277,871, and shareholder equity was negative $255,766. Cash and equivalents stood at $5,092.
Strategy
The company plans to develop and commercialize its KRAS gene-related business, aiming to address cancers including pancreatic, lung, and colorectal. It also intends to expand the SellaCare supplement into the cosmetic sector to build a sustainable revenue platform. Management describes entering six industry sectors, though specifics are not provided. The strategic focus appears to be on leveraging exclusive licenses to create multiple revenue streams.
Risks
- Going concern risk — Shareholder equity is negative $255,766 and cash is only $5,092, indicating potential inability to continue operations.
- Development stage uncertainty — The company is a development stage enterprise with no proven product or revenue model, making future success highly uncertain.
- Regulatory and market risk — Any KRAS-based treatments would face significant regulatory hurdles, but specifics are not disclosed.
- History of unreliable financials — The company has multiple 8-K filings indicating previously issued financials were not reliable, raising credibility concerns.
Outlook
Management does not provide specific forward-looking guidance in the provided excerpts. The company faces severe liquidity constraints and has not demonstrated a viable operating plan. Any future success depends on executing its KRAS and SellaCare strategies, but no milestones or timelines are disclosed.